Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by Vallon Pharmaceuticals, Inc., not GRI Bio, Inc., and reports an event dated December 23, 2021. Vallon is developing ADAIR, an abuse-deterrent formulation of immediate-release dextroamphetamine for attention deficit hyperactivity disorder and narcolepsy.
Material Event
Vallon announced that the last patient had completed the last visit in its pivotal SEAL study evaluating ADAIR. The filing does not provide study results, statistical outcomes, regulatory conclusions, or a commercialization timeline.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. No financial statements were included.
Guidance, Outlook, Risks, and Unusual Items
The announcement indicates completion of the final patient visit, but does not constitute reporting of topline efficacy or safety results. The filing does not provide management guidance, financial outlook, contingencies, or quantified risks. Future development and regulatory outcomes remain subject to the study results and applicable regulatory review.
Investor Verification Points
- Verify the issuer identity: the filing names Vallon Pharmaceuticals, Inc., ticker VLON, rather than GRI Bio, Inc.
- Verify the SEAL study topline results, including efficacy, safety, and statistical significance, when disclosed.
- Verify the timing and content of any regulatory submission or further development decision for ADAIR.
- Verify subsequent financing, liquidity, and operating updates because this filing contains no financial information.